{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:07:51Z","timestamp":1777525671141,"version":"3.51.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Education, Science and Sport of the Republic of Slovenia","award":["P3-0289"],"award-info":[{"award-number":["P3-0289"]}]},{"name":"Ministry of Education, Science and Sport of the Republic of Slovenia","award":["J3-1760"],"award-info":[{"award-number":["J3-1760"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>A hormone-active metastatic H\u00fcrthle cell thyroid carcinoma (HCTC) and Graves disease (GD) present a therapeutic challenge and is rarely reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We present a 64-year-old male patient, who had dyspnea and left hip pain lasting 4 months. He had clinical signs of hyperthyroidism and a tumor measuring 9\u200acm in diameter of the left thyroid lobe, metastatic neck lymph node and metastases in the lungs, mediastinum, and bones.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Laboratory findings confirmed hyperthyroidism and GD. Fine-needle aspiration biopsy and cytological investigation revealed metastases of HCTC in the skull and in the 8th right rib. A CT examination showed a thyroid tumor, metastatic neck lymph node, metastases in the lungs, mediastinum and in the 8th right rib measuring 20\u200a\u00d7\u200a5.6\u200a\u00d7\u200a4.5\u200acm, in the left acetabulum measuring 9\u200a\u00d7\u200a9\u200a\u00d7\u200a3\u200acm and parietooccipitally in the skull measuring 5\u200a\u00d7\u200a4\u200a\u00d7\u200a2\u200acm. Histology after total thyroidectomy and resection of the 8th right rib confirmed metastatic HCTC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The region of the left hip had been irradiated with concomitant doxorubicin 20\u200amg once weekly. When hyperthyroidism was controlled with thiamazole, a total thyroidectomy was performed. Persistent T3 hyperthyroidism, most likely caused by TSH-R-stimulated T3 production in large metastasis in the 8th right rib, was eliminated by rib resection. Thereafter, the patient was treated with 3 radioactive iodine-131 (RAI) therapies (cumulative dose of 515 mCi). Unfortunately, the tumor rapidly progressed after treatment with RAI and progressed 10\u200amonths after therapy with sorafenib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Despite treatment, the disease rapidly progressed and patient died due to distant metastases. He survived for 28\u200amonths from diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Simultaneous hormone-active HCTC and GD is extremely rare and prognosis is dismal. Concomitant external beam radiotherapy and doxorubicin chemotherapy, followed by RAI therapy, prevented the growth of a large metastasis in the left hip in our patient. However, a large metastasis in the 8th right rib presented an unresolved problem. Treatment with rib resection and RAI did not prevent tumor recurrence. External beam radiotherapy and sorafenib treatment failed to prevent tumor growth.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026384","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:41:14Z","timestamp":1624455674000},"page":"e26384","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Graves disease and metastatic hormonal-active H\u00fcrthle cell thyroid cancer"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-8767","authenticated-orcid":false,"given":"Nikola","family":"Besic","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Institute of Oncology Ljubljana"},{"name":"Faculty of Medicine Ljubljana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Vidergar-Kralj","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institute of Oncology Ljubljana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Zaletel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Ljubljana"},{"name":"Department of Nuclear Medicine, University Clinical Center Ljubljana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cvetka","family":"Grasic-Kuhar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Ljubljana"},{"name":"Department of Medical Oncology, Institute of Oncology Ljubljana, Zalo\u0161ka 2, Ljubljana, Slovenia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"R1-20250504","first-page":"829","article-title":"Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors","volume":"84","author":"Derwahl","year":"1999","journal-title":"JCEM"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0035-1559633","article-title":"Graves\u2019 disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies","volume":"47","author":"Morshed","year":"2015","journal-title":"Horm Metab Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-70-4-826","article-title":"Thyroid cancer and Graves\u2019 disease","volume":"70","author":"Mazzaferri","year":"1990","journal-title":"JCEM"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1210\/en.2008-0878","article-title":"Characterization of thyrotropin receptor antibody-induced signaling cascades","volume":"150","author":"Morshed","year":"2009","journal-title":"Endocrinology"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00268-004-7602-2","article-title":"Prognostic indications for H\u00fcrthle cell cancer","volume":"28","author":"Kushchayeva","year":"2004","journal-title":"World J Surg"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archotol.129.2.207","article-title":"Survival and prognosis in H\u00fcrthle cell carcinoma of the thyroid gland","volume":"129","author":"Bhattacharyya","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1186\/1471-2407-14-777","article-title":"Prognostic factors for disease-specific survival in 108 patients with H\u00fcrthle cell thyroid carcinoma: a single-institution experience","volume":"14","author":"Petric","year":"2014","journal-title":"BMC Cancer"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12885-016-2179-3","article-title":"Treatment and outcome of 32 patients with distant metastases of H\u00fcrthle cell thyroid carcinoma: a single-institution experience","volume":"16","author":"Besic","year":"2016","journal-title":"BMC Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.4158\/EP-2019-0201","article-title":"Prognosis of differentiated thyroid carcinoma in patients with Graves disease: a systematic review and meta-analysis","volume":"25","author":"Mekraksakit","year":"2019","journal-title":"Endocr Pract"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1210\/jc.2012-2843","article-title":"Increased mortality in patients with differentiated thyroid cancer associated with Graves\u2019 disease","volume":"98","author":"Pellegriti","year":"2013","journal-title":"JCEM"},{"key":"R13-20250504","first-page":"366","article-title":"Usefulness of free thyroxine to free triiodothyronine ratio for diagnostics of various types of hyperthyroidism","volume":"84","author":"Grmek","year":"2015","journal-title":"Zdrav Vestn"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/er.2012-1036","article-title":"The Na+\/I- symporter: mechanism and medical impact","volume":"35","author":"Portulano","year":"2014","journal-title":"Endocr Rev"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/105072503322238845","article-title":"The role of radioactive iodine in the treatment of Hurthle cell carcinoma of the thyroid","volume":"13","author":"Besic","year":"2003","journal-title":"Thyroid"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJM198310203091601","article-title":"Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer","volume":"309","author":"Maxon","year":"1983","journal-title":"N Engl J Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0889-8529(18)30317-7","article-title":"Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer","volume":"19","author":"Maxon","year":"1990","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12957-019-1626-4","article-title":"Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review","volume":"17","author":"Sheu","year":"2019","journal-title":"World J Surg Oncol"},{"key":"R19-20250504","first-page":"370","article-title":"Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer","volume":"62","author":"Danilovic","year":"2018","journal-title":"Arch Endocrinol Metab"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/thy.2011.0243","article-title":"Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or H\u00fcrthle cell thyroid carcinoma: a phase 2 study","volume":"22","author":"Besic","year":"2012","journal-title":"Thyroid"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1089\/thy.2018.0214","article-title":"Intensity-modulated radiation therapy with or without concurrent chemotherapy in nonanaplastic thyroid cancer with unresectable or gross residual disease","volume":"28","author":"Beckham","year":"2018","journal-title":"Thyroid"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.beem.2017.06.001","article-title":"Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: from the clinical trials to the real life","volume":"31","author":"Matrone","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/cancers13020317","article-title":"18F-FDG-PET\/CT in patients with advanced, radioiodine refractory thyroid cancer treated with lenvatinib","volume":"13","author":"Ahmaddy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:05:13Z","timestamp":1746338713000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026384"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":26,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026384","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"2021-04-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}